Nova Pharmaceutical Corp

Basic Information

6200 Freeport Ctr
Baltimore, MD, 21224

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. CHARACTERIZATION OF KAINATE & AMPA RECEPTOR ANTAGONIST

    Amount: $49,669.00

    STROKE IS THE MOST PROMINENT CNS DISORDER IN THE UNITED STATES AS WELL AS THE LEADING CAUSE OF DISABILITY AND THE THIRD LEADING CAUSE OF DEATH. HOWEVER, THERE ARE NO EFFECTIVE TREATMENTS AVAILABLE TO ...

    SBIR Phase I 1991 Department of Health and Human Services
  2. IDENTIFICATION OF SIGMA ANTAGONISTS

    Amount: $49,911.00

    DOPAMINE (D2) RECEPTOR ANTAGONISTS SUCH AS HALOPERIDOL AND CHLORPROMAZINE ARE MOST COMMONLY USED TO TREAT SCHIZOPHRENIA. HOWEVER, BOTH ACUTE AND CHRONIC ADMINISTRATION OF THESE DRUGS CAN RESULT IN THE ...

    SBIR Phase I 1991 Department of Health and Human Services
  3. DEVELOPMENT OF ENDOTHELIN-1 ANTAGONISTS

    Amount: $47,000.00

    ENDOTHELIN-1 (ET-1), A 21 AMINO ACID PEPTIDE, ACTING AT SPECIFIC RECEPTORS IN VASCULAR TISSUES HAS BEEN DEMONSTRATED TO INITIATE SUCH PHYSIOLOGICAL RESPONSES AS: DECREASES/INCREASES IN SYSTEMIC ARTERI ...

    SBIR Phase I 1991 Department of Health and Human Services
  4. DEVELOPMENT OF CORTICOTROPIN-RELEASING FACTOR ANTAGONISTS

    Amount: $447,349.00

    CORTICOTROPIN-RELEASING FACTOR (CRF), A 41-AMINO ACID PEPTIDE, ACTING AT SPECIFIC RECEPTORS IN THE BRAIN AND PITUITARY HAS BEEN DEMONSTRATED TO INITIATE BEHAVIORAL, PHYSIOLOGICAL AND NEUROENDOCRINE RE ...

    SBIR Phase II 1990 Department of Health and Human Services
  5. NOVEL CEREBROPROTECTIVE AGENTS

    Amount: $49,159.00

    THERE CURRENTLY EXISTS NO EFFECTIVE PROPHYLACTIC OR POST-HOC PHARMACOTHERAPY FOR MINIMIZING ISCHEMIA-INDUCED NEURONAL DAMAGE. MORE THAN ONE MILLION PEOPLE IN AMERICA ARE BELIEVED TO SUFFER NEURONAL DA ...

    SBIR Phase I 1990 Department of Health and Human Services
  6. INTERLEUKIN 1 REGULATION OF BRADYKININ RECEPTORS

    Amount: $49,611.00

    BRADYKININ (BK), SYNTHESIZED FOLLOWING MANY PATHOLOGICAL INSULTS, CAUSES SMOOTH MUSCLE CONTRACTION, INCREASED VASCULAR PERMEABILITY, AND STIMULATION OF NEURONAL PAIN RECEPTORS, ACTIONS GENERALLY MEDIA ...

    SBIR Phase I 1989 Department of Health and Human Services
  7. NOVEL APPETITE SUPPRESSANTS: DISCOVERY AND DEVELOPMENT

    Amount: $50,000.00

    THE SEARCH FOR A PHARMACOLOGICAL AGENT THAT WILL FACILITATE WEIGHT REDUCTION REMAINS AS ONE OF THE MOST CHALLENGING AREAS OF DRUG DEVELOPMENT. ANIMAL AND HUMAN DATA PROVIDE SOUND EVIDENCE THAT BODY WE ...

    SBIR Phase I 1988 Department of Health and Human Services
  8. GABA(B) RECEPTOR AGONISTS AND ANTAGONISTS

    Amount: $50,000.00

    EVIDENCE SUGGESTS RECEPTORS MEDIATING CNS RESPONSES TO -AMINOBUTYRIC ACID (GABA) ARE HETEROGENEOUS AND THE DESIGNATIONS OF GABA(A) AND GABA(B) HAVE BEEN ADVANCED TO DIFFERENTIATE MAJOR RECEPTOR SUBTYP ...

    SBIR Phase I 1988 Department of Health and Human Services
  9. NONCOMPETITIVE NMDA RECEPTOR ANTAGONISTS

    Amount: $46,000.00

    SUBSTANTIAL EVIDENCE INDICATES THAT EXCITATORY AMINO ACID (EAA) NEUROTRANSMISSION PLAYS A ROLE IN THE PATHOPHYSIOLOGY OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND THE NEURONAL DAMAGE THAT OCCURS FOLLO ...

    SBIR Phase I 1988 Department of Health and Human Services
  10. DEVELOPMENT OF CORTICOTROPIN-RELEASING FACTOR ANTAGONISTS

    Amount: $46,000.00

    N/A

    SBIR Phase I 1988 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government